Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Subscribe To Our Newsletter & Stay Updated